Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination.

Atmar RL, Baehner F, Cramer JP, Lloyd E, Sherwood J, Borkowski A, Mendelman PM; NOR-201 Study Group .

J Infect Dis. 2019 Jul 19;220(4):603-614. doi: 10.1093/infdis/jiz170.

PMID:
31001633
2.

An Exploratory Study of the Salivary Immunoglobulin A Responses to 1 Dose of a Norovirus Virus-Like Particle Candidate Vaccine in Healthy Adults.

Atmar RL, Cramer JP, Baehner F, Han C, Borkowski A, Mendelman PM.

J Infect Dis. 2019 Jan 9;219(3):410-414. doi: 10.1093/infdis/jiy529.

PMID:
30203081
3.

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.

Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, Aerssens A, De Coster I, Borkowski A, Baehner F, Van Damme P.

J Infect Dis. 2018 Jan 30;217(4):597-607. doi: 10.1093/infdis/jix572.

4.

Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.

Lindesmith LC, Mallory ML, Jones TA, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS.

J Infect Dis. 2017 Mar 15;215(6):984-991. doi: 10.1093/infdis/jix045.

5.

B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.

Ramani S, Neill FH, Ferreira J, Treanor JJ, Frey SE, Topham DJ, Goodwin RR, Borkowski A, Baehner F, Mendelman PM, Estes MK, Atmar RL.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00571-16. doi: 10.1128/CVI.00571-16. Print 2017 May.

6.

Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.

Atmar RL, Baehner F, Cramer JP, Song E, Borkowski A, Mendelman PM; NOR-201 Study Group.

J Infect Dis. 2016 Sep 15;214(6):845-53. doi: 10.1093/infdis/jiw259. Epub 2016 Jun 28.

7.

Serological Correlates of Protection against a GII.4 Norovirus.

Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinjé J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowski A, Baehner F, Goodwin R, Edmonds A, Mendelman PM.

Clin Vaccine Immunol. 2015 Aug;22(8):923-9. doi: 10.1128/CVI.00196-15. Epub 2015 Jun 3.

8.

Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial.

Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS.

PLoS Med. 2015 Mar 24;12(3):e1001807. doi: 10.1371/journal.pmed.1001807. eCollection 2015 Mar.

9.

Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine.

Sundararajan A, Sangster MY, Frey S, Atmar RL, Chen WH, Ferreira J, Bargatze R, Mendelman PM, Treanor JJ, Topham DJ.

Vaccine. 2015 Jan 15;33(4):568-76. doi: 10.1016/j.vaccine.2014.09.073. Epub 2014 Nov 22.

10.

Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinjé J, Gregoricus N, Frenck RW Jr, Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM.

J Infect Dis. 2015 Mar 15;211(6):870-8. doi: 10.1093/infdis/jiu497. Epub 2014 Sep 9.

11.

A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.

Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, Goodwin R, Borkowski A, Clemens R, Mendelman PM.

J Infect Dis. 2014 Dec 1;210(11):1763-71. doi: 10.1093/infdis/jiu337. Epub 2014 Jun 20.

PMID:
24951828
12.

Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.

McAllister L, Anderson J, Werth K, Cho I, Copeland K, Le Cam Bouveret N, Plant D, Mendelman PM, Cobb DK.

Lancet. 2014 Aug 23;384(9944):674-81. doi: 10.1016/S0140-6736(14)60524-9. Epub 2014 May 31.

PMID:
24881803
13.

Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis.

Richardson C, Bargatze RF, Goodwin R, Mendelman PM.

Expert Rev Vaccines. 2013 Feb;12(2):155-67. doi: 10.1586/erv.12.145. Review.

PMID:
23414407
14.

Norovirus vaccine against experimental human Norwalk Virus illness.

Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, Mendelman PM.

N Engl J Med. 2011 Dec 8;365(23):2178-87. doi: 10.1056/NEJMoa1101245.

15.

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.

El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, Bargatze RF, Sztein MB, Tacket CO.

J Infect Dis. 2010 Dec 1;202(11):1649-58. doi: 10.1086/657087. Epub 2010 Oct 27. Erratum in: J Infect Dis. 2011 Apr 1;203(7):1036.

16.

Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.

Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group.

Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064.

PMID:
18310199
17.
18.

A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine.

Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B; CAIV-T Transmission Study Group.

Pediatr Infect Dis J. 2006 Jul;25(7):590-5.

PMID:
16804427
19.

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.

Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM.

J Infect Dis. 2005 Apr 1;191(7):1116-22. Epub 2005 Feb 22.

PMID:
15747247
20.

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.

Belshe R, Lee MS, Walker RE, Stoddard J, Mendelman PM.

Expert Rev Vaccines. 2004 Dec;3(6):643-54. Review.

PMID:
15606348
21.

Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain.

Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K, Palladino G, Lee MS, Razmpour A, Stoddard J, Forrest BD.

Pediatr Infect Dis J. 2004 Nov;23(11):1053-5.

PMID:
15545863
22.

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.

Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, Hessel C, Cho I, Mendelman PM.

Clin Infect Dis. 2004 Oct 1;39(7):920-7. Epub 2004 Sep 7.

PMID:
15472840
23.

Measuring antibody responses to a live attenuated influenza vaccine in children.

Lee MS, Mahmood K, Adhikary L, August MJ, Cordova J, Cho I, Kemble G, Reisinger K, Walker RE, Mendelman PM.

Pediatr Infect Dis J. 2004 Sep;23(9):852-6.

PMID:
15361726
24.

Immunity to influenza in older adults with chronic obstructive pulmonary disease.

Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN.

J Infect Dis. 2004 Jul 1;190(1):11-9. Epub 2004 May 26.

PMID:
15195238
25.

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.

Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM.

Pediatr Infect Dis J. 2004 Feb;23(2):138-44.

PMID:
14872180
26.

Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.

Belshe RB, Mendelman PM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):745-67. Review.

PMID:
14753390
28.

Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study.

Gorse GJ, O'Connor TZ, Young SL, Mendelman PM, Bradley SF, Nichol KL, Strickland JH Jr, Paulson DM, Rice KL, Foster RA, Fulambarker AM, Shigeoka JW, Kuschner WG, Goodman RP, Neuzil KM, Wittes J, Boardman KD, Peduzzi PN.

Vaccine. 2003 May 16;21(17-18):2133-44.

PMID:
12706704
29.

Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.

Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, Larson S, Coelingh KL, Mendelman PM.

Vaccine. 2003 Mar 7;21(11-12):1224-31.

PMID:
12559802
30.

Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.

Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R; Cold-Adapted, Trivalent, Influenza Vaccine Study Group.

Pediatr Infect Dis J. 2003 Jan;22(1):28-34.

PMID:
12544405
31.

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.

Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB.

Pediatrics. 2002 Oct;110(4):662-72.

PMID:
12359778
32.

Safety, tolerability and immunogenicity of low dose Haemophilus influenzae type b conjugated to the outer membrane protein complex of Neisseria meningitidis group B.

Anderson EL, Frey S, Geldmacher K, Radley D, Lee A, Donnelly J, Mendelman PM, Dargan JM, Kaplan KM.

Pediatr Infect Dis J. 2002 Apr;21(4):350-2.

PMID:
12075771
33.

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma.

Redding G, Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G, Cordova J, Holmes SJ, Mendelman PM.

Pediatr Infect Dis J. 2002 Jan;21(1):44-8.

PMID:
11791098
34.

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.

Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, Blatter MM, Cho I, Holmes SJ, Cordova JM, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM.

J Infect Dis. 2001 Oct 1;184(7):909-13. Epub 2001 Aug 15.

PMID:
11509996
35.

Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.

Luce BR, Zangwill KM, Palmer CS, Mendelman PM, Yan L, Wolff MC, Cho I, Marcy SM, Iacuzio D, Belshe RB.

Pediatrics. 2001 Aug;108(2):E24.

PMID:
11483834
36.

Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants.

Lee MS, Mendelman PM, Sangli C, Cho I, Mathie SL, August MJ.

J Infect Dis. 2001 Apr 15;183(8):1281-4. Epub 2001 Mar 26.

PMID:
11262213
38.

Safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine (PedvaxHIB) in Papua New Guinean children.

Lehmann D, Kakazo M, Yarsley S, Javati A, Taime J, Saleu G, Namuigi P, Alpers MP, Mendelman PM, Staub T.

P N G Med J. 1998 Sep-Dec;41(3-4):102-11.

PMID:
10934551
39.

A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.

Blum MD, Dagan R, Mendelman PM, Pinsk V, Giordani M, Li S, Bohidar N, McNeely TB.

Vaccine. 2000 May 8;18(22):2359-67.

PMID:
10738092
40.

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.

Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M.

J Infect Dis. 2000 Mar;181(3):1133-7.

PMID:
10720541
41.

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.

Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, Belshe RB.

Vaccine. 2000 Mar 17;18(18):1902-9.

PMID:
10699339
42.

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M.

J Pediatr. 2000 Feb;136(2):168-75.

PMID:
10657821
43.

Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial.

Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, Arvin A.

J Clin Microbiol. 2000 Feb;38(2):839-45.

44.

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.

Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J.

JAMA. 1999 Jul 14;282(2):137-44.

PMID:
10411194
46.

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.

N Engl J Med. 1998 May 14;338(20):1405-12.

47.

IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults.

Storek J, Mendelman PM, Witherspoon RP, McGregor BA, Storb R.

Clin Infect Dis. 1997 Nov;25(5):1253-5. No abstract available.

PMID:
9402399
48.

Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis conjugate vaccine in 7.5 micrograms liquid formulation: a comparison of three lots with the 15.0 micrograms lyophilized formulation. Study Group for 7.5 micrograms Liquid PedvaxHIB.

Mendelman PM, Feeley L, Bird S, Staub T, Matthews H, Del Beccaro MA, Overturf G, Lee A, Ellis R, Staub J, Szymanski S, Donnelly J, Hennessey JP, Kniskern P.

Vaccine. 1997 Apr-May;15(6-7):775-81.

PMID:
9178481
49.

Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine.

Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N, Yagupsky P.

J Infect Dis. 1996 Dec;174(6):1271-8.

PMID:
8940218
50.

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants.

Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM.

J Pediatr. 1996 May;128(5 Pt 1):649-53.

PMID:
8627437

Supplemental Content

Loading ...
Support Center